Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Stephen C. Mack, Hendrik Witt, Rosario M. Piro, Lei Gu, Scott Zuyderduyn, Adrian M. Stütz, Xin Wang, Marco Gallo, Livia Garzia, Kory Zayne, Xiaoyang Zhang, Vijay Ramaswamy, Natalie Jäger, David Jones, Martin Sill, Trevor J. Pugh, Marina Ryzhova, Khalida Wani, David Shih, Renee Head, Marc Remke, Swneke D. Bailey, Thomas Zichner, Cláudia C. Faria, Mark Barszczyk, Sebastian Stark, Huriye Seker‐Cin, Sonja Hutter, Pascal D. Johann, Sebastian Bender, Volker Hovestadt, Theophilos Tzaridis, Adrian M. Dubuc, Paul A. Northcott, J.h. Peacock, Kelsey C. Bertrand, Sameer Agnihotri, Florence M.g. Cavalli, Ian D. Clarke, Kathleen Nethery-Brokx, Caretha L. Creasy, Sharad K. Verma, Jan Köster, Xiangji Wu, Yuan Yao, Till Milde, Patrick Sin‐Chan, Jennifer Zuccaro, Lynette Lau, Sérgio L. Pereira, Pedro Castelo‐Branco, Martin Hirst, Marco A. Marra, Stephen S. Roberts, Daniel W. Fults, Luca Massimi, Y. J. Cho, Timothy Van Meter, Wiesława Grajkowska, Bolesław Lach, Andreas E. Kulozik, Andreas von Deimling, Olaf Witt, Stephen W. Scherer, Xing Fan, Karin M. Muraszko, Marcel Kool, Scott L. Pomeroy, Nalin Gupta, Joanna J. Phillips, Annie Huang, Uri Tabori, Cynthia Hawkins, David Malkin, Paul Kongkham, William A. Weiss, Nada Jabado, James T. Rutka, Éric Bouffet, Jan O. Korbel, Mathieu Lupien, Kenneth Aldape, Gary D. Bader, Roland Eils, Peter Lichter, Peter B. Dirks, Stefan M. Pfister, Andrey Korshunov, Michael D. TaylorNature2014 · DOI
Hindbrain ependymomas represent a significant clinical challenge in pediatric neuro-oncology. Traditionally, cancer research focuses on identifying genetic mutations—the "broken" hardware of a cell—that drive tumor growth. However, for infants with posterior fossa ependymomas, decades of searching for these genetic drivers yielded little. A landmark study published in Nature has shifted this paradigm, revealing that these lethal tumors are driven not by genetic mutations, but by "broken" software: the epigenetic programming that governs gene expression.
The "Genetically Bland" Paradox
The research team utilized whole-genome (WGS) and whole-exome sequencing (WES) to profile 47 hindbrain ependymomas. The results were startling: there were virtually no recurrent significant mutations. The mutation rate in these tumors was found to be lower than almost any other sequenced cancer. This "genetically bland" landscape suggested that the malignancy's lethality was not a result of damaged genes, but rather a failure in how those genes are regulated.
Identifying the Epigenetic Driver: CIMP+
Through DNA methylation profiling, the researchers identified two distinct subgroups of posterior fossa (PF) ependymomas:
PFA (Posterior Fossa A): Primarily found in infants, these tumors carry a poor prognosis.
PFB (Posterior Fossa B): Found in older children and adults, these tumors generally have a much better prognosis.
The defining characteristic of the high-risk PFA group is a CpG island methylator phenotype (CIMP). In these tumors, thousands of gene promoters are hypermethylated, effectively silencing them. This discovery provided the first clear "driver" for a cancer that had previously appeared to have none.
PRC2 Convergence and Cellular Identity
The study found that the genes silenced by hypermethylation in PFA tumors were not random. Instead, they were the exact same targets normally regulated by the Polycomb Repressive Complex 2 (PRC2) in embryonic stem cells. By silencing these critical differentiation genes, the CIMP+ state "locks" the tumor cells in a primitive, undifferentiated state, preventing them from maturing into normal brain tissue and fueling their aggressive growth.
Therapeutic Vulnerabilities
The identification of an epigenetic driver opens new therapeutic avenues. Unlike genetic mutations, which are permanent changes to the DNA sequence, epigenetic modifications are chemically reversible.
The researchers tested this hypothesis using primary cultures and mouse xenograft models:
DNA Demethylation: Treatment with Decitabine, an FDA-approved DNA methylation inhibitor, significantly impaired tumor growth in vivo.
EZH2 Inhibition: Targeting the PRC2 complex directly using EZH2 inhibitors (such as GSK343) decreased H3K27 trimethylation and induced apoptosis (programmed cell death) in tumor cells, extending survival in animal models.
Conclusion and Future Directions
This research provides a robust biological explanation for why traditional chemotherapy has failed in infant ependymomas and offers a new roadmap for treatment. By identifying a three-gene biomarker panel (PKP1, CRIP1, CYP26C1), clinicians can now accurately identify high-risk PFA patients. While the initial trigger for the CIMP+ state remains a mystery, the discovery that these tumors are "undruggable" only by conventional means—and highly sensitive to epigenetic modifiers—marks a turning point in the fight against childhood brain cancer.
Summary updated
BibTeX
@inproceedings{mack2014epigenomic,
author = {Stephen C. Mack and Hendrik Witt and Rosario M. Piro and Lei Gu and Scott Zuyderduyn and Adrian M. Stütz and Xin Wang and Marco Gallo and Livia Garzia and Kory Zayne and Xiaoyang Zhang and Vijay Ramaswamy and Natalie Jäger and David Jones and Martin Sill and Trevor J. Pugh and Marina Ryzhova and Khalida Wani and David Shih and Renee Head and Marc Remke and Swneke D. Bailey and Thomas Zichner and Cláudia C. Faria and Mark Barszczyk and Sebastian Stark and Huriye Seker‐Cin and Sonja Hutter and Pascal D. Johann and Sebastian Bender and Volker Hovestadt and Theophilos Tzaridis and Adrian M. Dubuc and Paul A. Northcott and J.H. Peacock and Kelsey C. Bertrand and Sameer Agnihotri and Florence M.G. Cavalli and Ian D. Clarke and Kathleen Nethery-Brokx and Caretha L. Creasy and Sharad K. Verma and Jan Köster and Xiangji Wu and Yuan Yao and Till Milde and Patrick Sin‐Chan and Jennifer Zuccaro and Lynette Lau and Sérgio L. Pereira and Pedro Castelo‐Branco and Martin Hirst and Marco A. Marra and Stephen S. Roberts and Daniel W. Fults and Luca Massimi and Y. J. Cho and Timothy Van Meter and Wiesława Grajkowska and Bolesław Lach and Andreas E. Kulozik and Andreas von Deimling and Olaf Witt and Stephen W. Scherer and Xing Fan and Karin M. Muraszko and Marcel Kool and Scott L. Pomeroy and Nalin Gupta and Joanna J. Phillips and Annie Huang and Uri Tabori and Cynthia Hawkins and David Malkin and Paul Kongkham and William A. Weiss and Nada Jabado and James T. Rutka and Éric Bouffet and Jan O. Korbel and Mathieu Lupien and Kenneth Aldape and Gary D. Bader and Roland Eils and Peter Lichter and Peter B. Dirks and Stefan M. Pfister and Andrey Korshunov and Michael D. Taylor},
title = {{Epigenomic alterations define lethal CIMP-positive ependymomas of infancy}},
booktitle = {Nature},
year = {2014},
doi = {10.1038/nature13108},
}